Free Trial

Coronavirus Therapeutics Stocks List

Compare coronavirus therapeutics stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$308.16
-0.6%
$296.57
$218.44
$329.72
$166.24B0.62.02 million shs6.93 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$70.67
+3.2%
$65.74
$62.07
$87.86
$85.33B0.27.48 million shs31.30 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$1,053.14
+0.8%
$967.84
$684.80
$1,059.80
$115.08B0.13370,351 shs1.29 million shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.01
$0.01
$0.00
$0.42
$6.67M1.8276,909 shs97,319 shs
AbbVie Inc. stock logo
ABBV
AbbVie
$170.39
-1.0%
$163.89
$130.96
$182.89
$303.96B0.64.56 million shs12.31 million shs
GSK plc stock logo
GSK
GSK
$40.48
-0.7%
$42.55
$33.67
$45.92
$84.47B0.663.24 million shs3.49 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$883.88
-0.2%
$798.59
$434.34
$905.45
$842.05B0.362.34 million shs3.45 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+3.19%+0.54%+11.58%+35.73%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.00%+8.62%+6.80%-2.67%-8.94%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+1.60%+7.40%+8.88%+35.23%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%-5.00%-13.64%+18.75%-97.17%
AbbVie Inc. stock logo
ABBV
AbbVie
-0.11%+1.07%+7.64%-4.52%+24.50%
GSK plc stock logo
GSK
GSK
-0.02%-0.42%-10.38%-4.42%+15.18%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.07%+0.62%+9.37%+14.70%+95.12%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
4.7779 of 5 stars
2.35.03.33.92.92.51.9
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.9033 of 5 stars
3.23.03.34.13.92.51.9
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
3.6978 of 5 stars
2.42.00.02.32.62.52.5
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
AbbVie Inc. stock logo
ABBV
AbbVie
4.6507 of 5 stars
2.43.04.23.92.11.72.5
GSK plc stock logo
GSK
GSK
3.5924 of 5 stars
2.35.03.30.03.50.02.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.2747 of 5 stars
2.43.00.84.03.12.51.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.52
Moderate Buy$305.85-0.75% Downside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.33
Hold$83.4718.11% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.77
Moderate Buy$998.09-5.23% Downside
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/A
AbbVie Inc. stock logo
ABBV
AbbVie
2.86
Moderate Buy$179.645.43% Upside
GSK plc stock logo
GSK
GSK
2.57
Moderate Buy$47.0016.11% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$803.50-9.09% Downside

Current Analyst Ratings

Latest Coronavirus Therapeutics Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$80.00 ➝ $80.00
6/20/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
6/20/2024
GSK plc stock logo
GSK
GSK
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$185.00 ➝ $190.00
6/17/2024
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$1,050.00 ➝ $1,150.00
6/17/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
6/14/2024
Amgen Inc. stock logo
AMGN
Amgen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$328.00 ➝ $332.00
6/14/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$74.00 ➝ $74.00
6/12/2024
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$1,200.00 ➝ $1,229.00
6/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00
6/7/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$925.00 ➝ $957.00
(Data available from 6/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$28.19B5.86$26.20 per share11.76$11.65 per share26.45
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.12B3.25$9.23 per share7.66$18.26 per share3.87
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$13.12B8.85$43.63 per share24.14$236.63 per share4.45
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$62.84M0.08N/AN/A($0.05) per share-0.19
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.54$15.66 per share10.88$5.78 per share29.48
GSK plc stock logo
GSK
GSK
$37.71B2.22$5.15 per share7.86$7.74 per share5.23
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B24.62$7.61 per share116.17$11.44 per share77.26

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$6.72B$7.0044.0214.992.8012.74%156.21%10.82%8/1/2024 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$5.67B$0.36196.319.771.381.76%24.34%8.36%8/1/2024 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.95B$33.8531.1126.022.1629.45%16.83%13.16%8/1/2024 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3750.5614.082.2011.02%179.47%14.05%7/25/2024 (Estimated)
GSK plc stock logo
GSK
GSK
$6.13B$2.7614.678.941.2314.62%51.54%11.01%7/24/2024 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$6.79130.1745.841.9317.08%56.98%10.94%8/13/2024 (Estimated)

Latest Coronavirus Therapeutics Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024Q1 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.53$2.58+$0.05$2.68$8.94 billion$8.77 billion      
5/3/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion      
5/2/2024Q1 2024
Amgen Inc. stock logo
AMGN
Amgen
$3.76$3.96+$0.20$8.13$7.45 billion$7.45 billion    
5/2/2024Q1 2024
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.46$7.97-$0.49$9.67$3.19 billion$3.15 billion
5/1/2024Q1 2024
GSK plc stock logo
GSK
GSK
$0.94$1.09+$0.15$1.53$8.98 billion$9.34 billion
4/25/2024Q1 2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$1.49-$1.32+$0.17$0.70$6.36 billion$6.69 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.002.92%+10.01%128.57%13 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.084.36%+3.32%855.56%9 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.64%+7.84%183.98%52 Years
GSK plc stock logo
GSK
GSK
$1.473.63%-18.18%53.26%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.59%+15.15%76.58%N/A

Latest Coronavirus Therapeutics Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/20/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.6%7/15/20247/15/20248/15/2024
5/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.37623.2%5/16/20245/17/20247/11/2024
4/23/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.774.71%6/14/20246/14/20246/27/2024
5/6/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.300.69%5/15/20245/16/20246/10/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
11.96
1.42
0.98
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.31
1.08
0.94
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.10
5.27
4.51
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A
AbbVie Inc. stock logo
ABBV
AbbVie
7.93
0.94
0.83
GSK plc stock logo
GSK
GSK
1.15
0.87
0.58
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.90
1.35
1.03

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
GSK plc stock logo
GSK
GSK
15.74%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
26,700536.43 million532.73 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
18,0001.25 billion1.24 billionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
13,450110.19 million101.94 millionOptionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
949551.28 million536.95 millionOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.76 billionOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.41 million949.17 millionOptionable

Coronavirus Therapeutics Stocks Headlines

Recent News About These Companies

Eli Lilly and Company (NYSE:LLY) Shares Down 0.3%
Financial markets news icon
MarketBeat Week in Review – 6/17 - 6/21 (LLY)
Eli Lilly and Company (NYSE:LLY) Sets New 12-Month High at $901.70
Eli Lilly and Company logo with Medical background
Eli Lilly and Company (NYSE:LLY) Trading Down 0.3%
Hype Busters: 3 Overvalued Stocks Ready for a Reality Check
Eli Lilly and Company (NYSE:LLY) Shares Up 0.7%
Eli Lilly and Company logo with Medical background
Eli Lilly and Company (NYSE:LLY) Trading Up 0.7%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

Company Descriptions

Amgen logo

Amgen

NASDAQ:AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

NASDAQ:REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Sorrento Therapeutics logo

Sorrento Therapeutics

NASDAQ:SRNE
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.